The result was Speedy Keep. Wamper
Ampligen entry contains big mistakes (e.g. Ampligen phase III trial for CFS was completed in 2004, Bioclones' marketing rights are being challenged by Hemispherx Biopharma, Ampligen raw materials are no longer manufactured by Ribotech) and lacks relevant indispensable elements (e.g. the results of the phase II and phase III trials for Ampligen for CFS, relevant Ampligen patents)while containing a lot of irrelevant material (patent to infuse tobacco ). The serious side-effects that are referred to lack correct evidence. The link that is offered is a testimony of one person who cannot even prove that her problems were caused by Ampligen... It's a hopeless task to correct all the mistakes and the set-up of this entry, so someone should start from scratch. Well, as I don't feel called upon to contribute, let me suggest that someone who is called upon to contribute to compare the Wikipedia Ampligen entry with the information in the following fairly dependable research report http://www.boenningandscattergood.com/research/CI/HEB%20%282006.12.1%29.pdf and in the Sec filings of Hemispherx Biopharma http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000946644&owner=include I for one, as Ampligen is an experimental drug, would wait for an EMEA European Public Assessment Report (EPAR) http://www.emea.eu.int/htms/human/epar/eparintro.htm or FDA equivalent. Wamper 15:35, 12 February 2007 (UTC) reply
After reading the Ampligen entry, I want to say that to me it is not credible that Thedreamdied on the one hand knows all the things he knows, and doesn't know all the things he has wrong on Ampligen in his article. It's clear to me that Thedreamdied's aim was not to write an informative, well-balanced, well-documented article on Ampligen, but to discredit Ampligen by stating e.g. that it has serious side-effects, a false and defamatory statement, or by stating that "As of 2007, a new trial is recruiting" while, in order to suggest that the completed phase III will not be sufficient for the FDA, Thedreamdied "forgets" to add that this concerns an open label protocol study, carried out to obtain additional safety data (Phase 3 studies), that are typically used when the controlled trial has ended and treatment is continued so that the subjects and the controls may continue to receive the benefits of the investigational drug until marketing approval is obtained. http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html. Donklo 22:37, 12 February 2007 (UTC) reply
The result was Speedy Keep. Wamper
Ampligen entry contains big mistakes (e.g. Ampligen phase III trial for CFS was completed in 2004, Bioclones' marketing rights are being challenged by Hemispherx Biopharma, Ampligen raw materials are no longer manufactured by Ribotech) and lacks relevant indispensable elements (e.g. the results of the phase II and phase III trials for Ampligen for CFS, relevant Ampligen patents)while containing a lot of irrelevant material (patent to infuse tobacco ). The serious side-effects that are referred to lack correct evidence. The link that is offered is a testimony of one person who cannot even prove that her problems were caused by Ampligen... It's a hopeless task to correct all the mistakes and the set-up of this entry, so someone should start from scratch. Well, as I don't feel called upon to contribute, let me suggest that someone who is called upon to contribute to compare the Wikipedia Ampligen entry with the information in the following fairly dependable research report http://www.boenningandscattergood.com/research/CI/HEB%20%282006.12.1%29.pdf and in the Sec filings of Hemispherx Biopharma http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000946644&owner=include I for one, as Ampligen is an experimental drug, would wait for an EMEA European Public Assessment Report (EPAR) http://www.emea.eu.int/htms/human/epar/eparintro.htm or FDA equivalent. Wamper 15:35, 12 February 2007 (UTC) reply
After reading the Ampligen entry, I want to say that to me it is not credible that Thedreamdied on the one hand knows all the things he knows, and doesn't know all the things he has wrong on Ampligen in his article. It's clear to me that Thedreamdied's aim was not to write an informative, well-balanced, well-documented article on Ampligen, but to discredit Ampligen by stating e.g. that it has serious side-effects, a false and defamatory statement, or by stating that "As of 2007, a new trial is recruiting" while, in order to suggest that the completed phase III will not be sufficient for the FDA, Thedreamdied "forgets" to add that this concerns an open label protocol study, carried out to obtain additional safety data (Phase 3 studies), that are typically used when the controlled trial has ended and treatment is continued so that the subjects and the controls may continue to receive the benefits of the investigational drug until marketing approval is obtained. http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html. Donklo 22:37, 12 February 2007 (UTC) reply